April 2023

Factors Associated with the Retention of Secukinumab in Patients with Axial Spondyloarthritis in Real-world Practice: Results from a Retrospective Study (FORSYA)

RMD Open 2023;9:e002802 doi: 10.1136/rmdopen-2022-002802

This study reported the overall retention of secukinumab in daily practice in the period following its approval in France was approximately 59% at 1 year in axSpA patients. The aim of this study was to determine whether OSI were predictive of secukinumab retention at 1 year.

Keywords:

February 2023

Efficacy and Safety of Bimekizumab in Axial Spondyloarthritis: Results of Two Parallel Phase 3 Randomised Controlled Trials

Ann Rheum Dis. 2023 Jan 17 doi: 10.1136/ard-2022-223595

Bimekizumab may therefore offer patients with axSpA an effective treatment option with a novel mode of action.

Keywords:

Impact of Cardiovascular Risk Enrichment on Incidence of Major Adverse Cardiovascular Events in the Tofacitinib Rheumatoid Arthritis Clinical Programme

Ann Rheum Dis. 2023;82(4):575–577 doi: 10.1136/ard-2022-223406

Data suggest that an important difference between P123LTE and ORAL Surveillance was the proportion of patients with a history of atherosclerotic CV disease (ASCVD).

Keywords:

January 2023

Safety and Efficacy of Bimekizumab in Patients With Active Ankylosing Spondylitis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study

Arthritis Rheumatol. 2022;74:1943–58

In this open-label extension study of BE AGILE, the safety profile of bimekizumab was found to be consistent with previously demonstrated findings, and no new safety signals were identified. The objective was to assess the long-term safety, tolerability, and efficacy of bimekizumab in patients with active AS.

Keywords: